The estimated Net Worth of Steven J Mento is at least $1.8 Milion dollars as of 4 May 2018. Steven Mento owns over 60,000 units of Conatus Pharmaceuticals stock worth over $33,600 and over the last 22 years he sold CNAT stock worth over $510,825. In addition, he makes $1,251,370 as Director at Conatus Pharmaceuticals.
Steven has made over 13 trades of the Conatus Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of CNAT stock worth $59,400 on 4 May 2018.
The largest trade he's ever made was exercising 60,000 units of Conatus Pharmaceuticals stock on 4 May 2018 worth over $59,400. On average, Steven trades about 7,992 units every 109 days since 2002. As of 4 May 2018 he still owns at least 60,000 units of Conatus Pharmaceuticals stock.
You can see the complete history of Steven Mento stock trades at the bottom of the page.
Dr. Steven J. Mento Ph.D. serves as Director of the Company. Dr. Mento also served as chairman of our board of directors. Dr. Mento has over 30 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, Dr. Mento was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. Dr. Mento guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, Dr. Mento served as President of Chiron Viagene, Inc. (subsequently Chiron Technologies, Center for Gene Therapy), and Vice President of Chiron Corporation from 1995 to 1997. Dr. Mento was Vice President of R&D at Viagene from 1992 to 1995. Prior to Viagene, Dr. Mento held various positions at American Cyanamid Company from 1982 to 1992. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid. Dr. Mento currently serves on the boards of directors of BIOCOM, BIO, BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc. and various academic and charitable organizations. Dr. Mento holds a B.A. in Microbiology from Rutgers College, and an M.S. and Ph.D. both in Microbiology from Rutgers University. Mento is qualified to serve on our board of directors because of his extensive knowledge of our business, as well as his over 30 years of experience in the biotechnology and pharmaceutical industries, including executive leadership in several pharmaceutical companies.
As the Director of Conatus Pharmaceuticals, the total compensation of Steven Mento at Conatus Pharmaceuticals is $1,251,370. There are no executives at Conatus Pharmaceuticals getting paid more.
Steven Mento is 67, he's been the Director of Conatus Pharmaceuticals since 2020. There are 1 older and 5 younger executives at Conatus Pharmaceuticals. The oldest executive at Conatus Pharmaceuticals, Inc. is Daniel Kisner, 73, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO, CA, 92127.
Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over $0 worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth $17,229,485 . The most active insiders traders include Shahzad Malik, Paul H Klingenstein a Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of $47,160. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth $59,400.
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
Conatus Pharmaceuticals executives and other stock owners filed with the SEC include: